title: Should all CMV infections after bone marrow transplantation be treated?
authors.affiliation: CHR 59037 Lille, France.
authors.forename: J P
authors.initials: JP
authors.lastname: Jouet
authors.forename: A
authors.initials: A
authors.lastname: Draoui
authors.forename: T
authors.initials: T
authors.lastname: Facon
authors.forename: M P
authors.initials: MP
authors.lastname: Noel-Walter
authors.forename: P
authors.initials: P
authors.lastname: Wattre
authors.forename: P
authors.initials: P
authors.lastname: Fenaux
authors.forename: B
authors.initials: B
authors.lastname: Dupriez
authors.forename: P
authors.initials: P
authors.lastname: Morel
authors.forename: F
authors.initials: F
authors.lastname: Bauters
mesh_terms: D016026:Bone Marrow Transplantation / Q000009:adverse effects* / Q000401:mortality; D003131:Combined Modality Therapy; D003586:Cytomegalovirus Infections / Q000188:drug therapy / Q000209:etiology / Q000401:mortality / Q000628:therapy*; D005602:France / Q000453:epidemiology; D015774:Ganciclovir / Q000627:therapeutic use; D006801:Humans; D007116:Immunization, Passive; D009369:Neoplasms / Q000401:mortality / Q000601:surgery; D011658:Pulmonary Fibrosis / Q000209:etiology / Q000401:mortality / Q000628:therapy
chemical_list: D015774:Ganciclovir